Histamine & Bradykinin Pharmacology · Module 1 of 4

Histamine Biology, Receptors, and Physiological Roles

Storage sites, receptor subtypes, signaling, and pathophysiological roles

Histamine is synthesized from histidine by histidine decarboxylase in a single irreversible step, stored in granules bound to heparin proteoglycans, and inactivated extracellularly (no reuptake transporter) by histamine N-methyltransferase in peripheral tissues and diamine oxidase in the GI tract; four distinct cell populations store histamine: mast cells (tissue-resident, largest peripheral reservoir, IgE-mediated and non-immunological degranulation), basophils (circulating, IgE-mediated, late-phase reactions), enterochromaffin-like cells (gastric oxyntic mucosa, stimulated by gastrin and acetylcholine, paracrine H2 activation of parietal cells), and histaminergic neurons (tuberomammillary nucleus, wakefulness via H1, first-generation antihistamine sedation).
H1 (Gq) and H2 (Gs) are the two clinically dominant receptors for Step 1 — H1 activates phospholipase C → IP3/DAG → ↑intracellular Ca²⁺; expressed on vascular endothelium (vasodilation/permeability), bronchial smooth muscle (bronchoconstriction), sensory C fibers (pruritus), and CNS neurons (wakefulness); H1 antihistamines are technically inverse agonists (stabilize inactive receptor conformation), not simple competitive antagonists; H2 activates adenylyl cyclase → ↑cAMP → PKA → H⁺/K⁺-ATPase → acid secretion in gastric parietal cells.
H3 (Gi, presynaptic autoreceptor in CNS) inhibits histamine synthesis and release — pitolisant (H3 inverse agonist) disinhibits histaminergic neurons for narcolepsy; H4 (Gi, immune cells) modulates eosinophil chemotaxis — no Step 1-level approved drug; histamine also contributes modest cardiac effects via H2 on cardiomyocytes (↑HR and contractility via cAMP — contributes to tachycardia in anaphylaxis alongside dominant H1-mediated vasodilation).
Non-immunological histamine release triggers the same clinical syndromes as IgE-mediated release — direct mast cell activators include: opioids (morphine, codeine), vancomycin (Red Man Syndrome — rate-dependent, not IgE), tubocurarine and atracurium (more histamine release than rocuronium/vecuronium — relevant during anesthesia), radiocontrast media (risk reduced with modern low-osmolality non-ionic agents), C3a and C5a anaphylatoxins (complement activation); all managed identically to IgE-mediated anaphylaxis.
Angioedema without urticaria is the key distinguishing feature of bradykinin-mediated disease — histamine-mediated angioedema virtually always occurs with urticaria; bradykinin-mediated angioedema (hereditary angioedema, ACE inhibitor-induced) occurs without urticaria and does NOT respond to antihistamines, corticosteroids, or epinephrine; epinephrine is the only first-line treatment for IgE-mediated anaphylaxis — antihistamines are adjuncts only and have no effect on bronchospasm or hemodynamic collapse.

Abbreviations: HDC = histidine decarboxylase · HNMT = histamine N-methyltransferase · DAO = diamine oxidase · ECL = enterochromaffin-like · TMN = tuberomammillary nucleus · IgE = immunoglobulin E · Gq = G protein q-alpha · Gs = G protein s-alpha · Gi = G protein i-alpha · PLC = phospholipase C · IP3 = inositol trisphosphate · cAMP = cyclic adenosine monophosphate · PKA = protein kinase A · NO = nitric oxide · PAF = platelet-activating factor · ACE = angiotensin-converting enzyme

Histamine Storage Sites and Cellular Distribution

Immune System

Mast Cells

Tissue-resident: skin, airways, gut mucosa, blood vessel adventitia
Largest peripheral histamine reservoir
IgE-mediated crosslinking → immediate degranulation (seconds)
Also: opioids, vancomycin, tubocurarine, radiocontrast, C3a/C5a

Immune System

Basophils

Circulating granulocytes; share high-affinity IgE receptor with mast cells
Not tissue-resident normally; recruited in late-phase allergic reactions
Contribute to blood-phase histamine release

Gastric Mucosa

ECL Cells

Oxyntic gastric mucosa neuroendocrine cells
Stimulated by gastrin (antral G cells) and acetylcholine (vagal)
Paracrine H2 activation of adjacent parietal cells → acid secretion
Dominant target of H2 blocker therapy

Central Nervous System

Histaminergic Neurons

Cell bodies in tuberomammillary nucleus (posterior hypothalamus); sole CNS histaminergic population
Project to cortex, hippocampus, striatum, brainstem
Active during wakefulness; H1 promotes cortical arousal
1st-generation antihistamines cross BBB → CNS H1 blockade → sedation

Histamine Receptor Subtypes

Receptor	G Protein	Key Location	Primary Effect	Drug Target
H1	Gq → PLC → IP3/DAG → ↑Ca²⁺	Vascular endothelium, bronchial smooth muscle, sensory C fibers, CNS neurons (TMN)	Vasodilation + ↑permeability; bronchoconstriction; pruritus; wakefulness; H1 antihistamines are inverse agonists (stabilize inactive conformation)	H1 antihistamines — 1st-generation (sedating) and 2nd-generation (non-sedating)
H2	Gs → ↑cAMP → PKA	Gastric parietal cells (dominant); cardiac myocytes (minor)	H⁺/K⁺-ATPase activation → acid secretion; minor: ↑HR and contractility (contributes to anaphylactic tachycardia)	H2 blockers — cimetidine, famotidine, ranitidine
H3	Gi → ↓cAMP	Presynaptic autoreceptor on histaminergic neurons (CNS)	Inhibits histamine synthesis and release (negative feedback loop)	Pitolisant (H3 inverse agonist) — narcolepsy; low Step 1 yield otherwise
H4	Gi → ↓cAMP	Immune cells (mast cells, basophils, eosinophils)	Eosinophil chemotaxis; immune cell modulation	No approved Step 1-level drug

Pathophysiological Roles and Clinical Limits of Antihistamines

Skin — H1-Mediated

Triple Response of Lewis

Red spot: local arteriolar vasodilation (H1 on vascular endothelium → ↑NO → vasodilation)
Wheal: plasma extravasation; H1-mediated ↑vascular permeability; fluid accumulates in dermis
Flare: axon reflex — surrounding erythema beyond injection site; dilates surrounding arterioles
Itch: H1 activation of sensory C fibers
= skin correlate of urticaria; reproduces local vascular events of acute allergy in miniature

Systemic — Multimediator

Anaphylaxis

Massive mast cell + basophil degranulation releases histamine alongside prostaglandins, leukotrienes, PAF, and tryptase
Histamine = primary mediator of urticaria, angioedema, flushing, and vascular collapse (H1 vasodilation)
Antihistamines reduce pruritus/urticaria — they do NOT reverse bronchospasm or hemodynamic collapse
Epinephrine is the ONLY first-line treatment: α1 → reverses vasodilation; β2 → reverses bronchospasm; β1 → supports cardiac output

Angioedema Without Urticaria — Critical Distinction

Histamine-mediated angioedema occurs virtually always in the context of urticaria. Bradykinin-mediated angioedema — hereditary angioedema and ACE inhibitor-induced angioedema — occurs without urticaria. A patient with angioedema but no urticaria, or any patient on an ACE inhibitor who develops angioedema, must not be treated as histamine-mediated disease. These patients will NOT respond to antihistamines, corticosteroids, or epinephrine and require bradykinin-specific therapy (icatibant, C1-esterase inhibitor concentrate, or fresh frozen plasma). Failure to recognize this distinction can be fatal. Bradykinin pharmacology is covered in Module 4.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter on Histamine, Serotonin, and the Ergot Alkaloids	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill; 2023
Simons FE, Simons KJ.	Histamine and H1-antihistamines: celebrating a century of progress	J Allergy Clin Immunol. 2011;128(6):1139–1150
Galli SJ, Tsai M, Piliponsky AM.	The development of allergic inflammation	Nature. 2008;454(7203):445–454
Schubert ML, Peura DA.	Control of gastric acid secretion in health and disease	Gastroenterology. 2008;134(7):1842–1860
Haas HL, Sergeeva OA, Selbach O.	Histamine in the nervous system	Physiol Rev. 2008;88(3):1183–1241
Sampson HA, Munoz-Furlong A, Campbell RL, et al.	Second symposium on the definition and management of anaphylaxis: summary report	J Allergy Clin Immunol. 2006;117(2):391–397
Zuberbier T, Maurer M.	Urticaria: current opinions about etiology, diagnosis and therapy	Acta Derm Venereol. 2007;87(3):196–205
Leurs R, Church MK, Taglialatela M.	H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects	Clin Exp Allergy. 2002;32(4):489–498
Haas H, Panula P.	The role of histamine and the tuberomamillary nucleus in the nervous system	Nat Rev Neurosci. 2003;4(2):121–130
Thurmond RL, Gelfand EW, Dunford PJ.	The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines	Nat Rev Drug Discov. 2008;7(1):41–53
Holgate ST, Polosa R.	Treatment strategies for allergy and asthma	Nat Rev Immunol. 2008;8(3):218–230
Dauvilliers Y, Bassetti C, Lammers GJ, et al.	Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial	Lancet Neurol. 2013;12(11):1068–1075